I have a tiny bump near the top of my clitoris. I support this campaign and I believe that FGM is impermissible. This weekend I starting having some vaginal itching after my boyfriend and I last had sex Friday night (and it was slightly more rough and longer than normal). I already know I have HSV1, so thought it was an outbreak, but the doctor who treated it (the second time I had it) said it’s not HSV; that it was some kind of skin infection. I would also personally love to see an end to the practice. koortslipje op jouw klit is niet zo fijn bijvbSnakeydonderdag 7 oktober 2004 @ 20:30quote:Op donderdag 7 oktober 2004 20:28 schreef verward het volgende: Wat ik niet weet is dus of ik zoals hierboven al vernoemd gewoon moet laten, dat ik schijnbaar in een supergeile periode zit ofzo, of dat het dus iets is waarmee ik naar een doctor zou moeten. An additional consequence to vulvovaginal laxity is reduced sensation during coitus, with a potential negative effect on sexual satisfaction and quality of life4–7.
aur jate hue bola ki chai bhej deta hu aapke liye aur chala gaya. I must ask, on what are they basing these assertions? Complications include shoulder dystocia, traumatic delivery, fractures, brachial plexus injury (Erb’s palsy), perinatal asphyxia, neonatal hypoglycaemia, meconium aspiration. 1) to the entire region of vulva, perineum, and perianus. This might reduce the pain but also may help to treat something else might be happening. Orgasmic dysfunction, reduced friction during sex due to ‘looseness’, and other aspects of laxity-related changes are perceived to negatively impact the sexual experience in a variety of ways. you can get hold of this at wal-mart, or drug shop- keep your self unbelievably clean, purify up every morning and every night, and especially after sex.
I know this is something that is typically brought on by menopause. There are products out there than can attach to his penis (feelers, ticklers, etc) that would give you further vaginal sensation as well. In the past, treatment of vulvovaginal laxity and related aspects lay within a short spectrum heavily weighted at the ends, with non-invasive (but minimally effective) Kegel exercises to strengthen the pelvic floor versus costly, invasive surgery at the other end. A 2012 physician member survey conducted by the International Urogynecological Association (IUGA) assessed the attitudes and practices regarding vaginal laxity6; of the 563 respondents, 84% stated belief that vaginal laxity was underreported, 95% believed vaginal laxity impacted patient sexual function, and 57% considered it to greatly affect quality of life. All respondents felt vaginal laxity was the dominant physical change experienced by subjects after vaginal delivery. As for treatment, all surveyed physicians recommended Kegel exercises along with physical therapy, with approximately 54% offering or recommending surgical intervention, although 83% of respondents were concerned about dyspareunia (painful sexual intercourse) as an associated risk of surgery. Only recently have alternatives appeared to fill the wide gulf between the two ends of the spectrum.
Positive feedback is greatly appreciated. Vulvovaginal rejuvenation with devices harnessing laser or radiofrequency (RF) energy (among others), as in aesthetic dermatology and plastic surgery on the face, neck, and décolleté9–10, is a fairly new concept with real potential for success. Numerous studies in aesthetic medicine have demonstrated tissue contraction and determined a therapeutically ideal temperature range (40°C to 45°C) in which neocollagenesis (via the healing cascade) is stimulated without causing unnecessary damage to the skin or integral tissue structures. A landmark study by Millheiser and colleagues in 201011 investigated transurethral monopolar RF for vaginal laxity after vaginal childbirth. Subjects (n=24, age range 25 to 44) were premenopausal women and had at least one full term vaginal delivery. Investigators used a seven point vaginal laxity scale (vaginal laxity questionnaire, or VLQ) to assess subjective patient perception of laxity and improvement (with ratings of 1=very loose, 2=moderately loose, 3=slightly loose, 4=neither loose nor tight, 5=slightly tight, 6=moderately tight, and 7=very tight). You may not need 8 hours, however get as many hours as it takes for you to feel fully rested.
Cryogen cooling was used concurrently with the RF probe inside the vagina to manage potential unwanted thermal damage due to overtreatment. At 1 month post-treatment 67% of patients reported improvements of 2 to 4 points on the VLQ and all patients reported at least one point of improvement. By follow-up at 6 months, approximately 87% of subjects reported improvements of 2 to 4 points. Of the 12 subjects who had reported diminished sexual function following delivery, all reported notable improvement to sexual function as well. Sekiguchi et al.8 more recently reported on a prospective study of low-energy RF for vaginal introital laxity of 30 premenopausal women (age range 21 to 52 years), each receiving a 30-minute treatment with evaluations at 6 and 12 months post‑treatment. Statistically significant improvements in sexual function, vaginal laxity, and reductions in distress during sexual activity were noted at 6 months and maintained through the 12-month endpoint, with no adverse events reported. Note: Sexual attraction and romantic attraction are also not tied together.
Transcutaneous temperature controlled radiofrequency (TTCRF) brings with it numerous advantages for the treatment of skin laxity14. RF is an established modality for tissue tightening via stimulation of neocollagenesis, denaturation of collagen, contraction, and activation of the healing cascade. This was shown in a histological study of RF in animal studies15. Thus, tissue temperature is modulated by controlling the power (the electrical voltage delivered to the RF electrode) in relation to tissue impedance, which raises tissue temperature in the proximity of the RF electrode. Thermistors and thermocouples within the treatment probe provide feedback to the device, which controls power to modulate energy deposition and maximize therapeutic relevancy without causing damage and minimizing the potential for patient discomfort. Unless you have a REAL stank ass vagina, where you haven’t been washing for weeks/months I’m sure they’ve seen it before. But even “hospitalized” or “minor” circumcisions are not without their risks and complications: in 2011, nearly a dozen boys were treated for “life threatening haemorrhage, shock or sepsis” as a result of their non-therapeutic circumcisions at a single children’s hospital in Birmingham in England.
The treatment probe is of a proprietary design developed with expert physician input. During TTCRF treatment, the probe tip is passed back and forth slowly and with wide sweeps over the desired zone of treatment for 3 to 5 minutes, until the tissue is gradually heated to the therapeutically relevant level to induce tightening of the skin, mucosa, and fascia as well as stimulate neocollagenesis. What does this mean? The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of TTCRF as well as anecdotally document possible ancillary beneficial effects of treatment, to promote further study. In this prospective study, 23 subjects (age range 26–58 years, mean 43.6; median vaginal births=2, mean parity 1.7; 5 menopausal, 6 perimenopausal) presented with self-described mild to moderate primary or secondary vulvovaginal laxity. SASUR NE BAHU SE SHADI KARKE APNA BANAYA – YUM Stories (http://yumstories.com/index.php%3Ftopic%3D50103.12) Mr. But I have never heard of female circumcision?
Intracranial calcifications (may not have shadowing) suggests CMV (in normal-size head suggests toxoplasmosis), DDx tubers in TS. The suggestive clinical symptoms or signs were irregular borders, black clinical appearance, recent growth, and/or recent onset of pruritus. Exclusion criteria included pelvic surgery within 5 years of study commencement, presence of major psychiatric conditions or related need for medication, chronic use of anti-inflammatory agents (including steroids) and immunosuppressants, pregnancy or planned pregnancy within the study period, recent abnormal Papnicolaou test result, presence of vulvar lesions or disease (dermatitis, human papillomavirus, herpes simplex, vulvar dystrophy), or the presence of any condition or circumstance that, in the opinion of the investigating physician, may be unsafe or otherwise interfere with the study. Informed consent was obtained from all subjects prior to commencement of the study. Pre-treatment digital photography was performed at baseline along with physician evaluation of patients. Treatment was performed in a clinical office setting without anesthesia. Great.
A neutral return pad was placed underneath the buttocks of the subject, and a coupling gel was used as a lubricant for treatment with the TTCFR device. Once patients were settled and comfortable they were treated using the TTCRF device (ThermiVa, ThermiAesthetics, Inc., Southlake, TX) for approximately 5 minutes per zone (left and right labia majora; and the ventral, dorsal, left and right surfaces of the vaginal wall). The labia majora were treated first; the treatment tip was applied to each labial surface bilaterally from the lowest edge of the mons pubis to the perineal body and laterally to the crural folds. The clinical endpoint was achievement of the target temperature range of 40°C to 45°C for approximately 3–5 minutes per zone (or longer, depending on heat tolerance). This was followed by treatment of the mucosal surface of the vaginal introitus starting at the hymenal ring and advancing to approximately 4 to 9 cm into the cavity for each zone of the vaginal wall (ventral, dorsal, left and right). For each zone the treatment tip is inserted into the vagina with the emitter surface facing the desired direction, and energy is applied with the treatment cannula using an in-and-out motion. The clinical endpoint was achievement of the target temperature in the range of 40°C to 45°C for approximately 3–5 minutes per zone (or longer, depending on heat tolerance); treatment was repeated identically for each of the four vaginal surfaces.
Total treatment time was less than 30 minutes. A complete course of therapy consisted of three treatments with the TTCRF device, at an interval of approximately 4–6 weeks. Patients were offered up to three treatments but not required to undergo all three. Evaluation of vulvovaginal laxity was made on a 7 point scale by both the investigating physician and patient self-assessment via VLQ11; the patient assessment data was used for analysis. A 6 point sexual satisfaction scale11 was also used by patients to rate sexual satisfaction. Table 1 delineates these scales. Assessment occurred at baseline, 10 days after first treatment, before second treatment, before third treatment, and 30 days after the third treatment session.
In addition, patients were asked to give a global assessment asking if they would recommend the procedure to a friend or family member (a 5 point scale where 1=strongly agree and 5=strongly disagree) and to rate overall satisfaction with the procedure (a 5 point scale where 1=very unsatisfied and 5=very satisfied). Of the original 23 subjects, 6 were lost to follow-up before each of the second and third treatments, reportedly due to high satisfaction with results not necessitating further treatment in the opinion of the patient. There were no burns, blisters or major complications during or after treatments, which were described as pleasant and very comfortable. All patients (n=23) received at least one treatment, with 17 undergoing a second treatment and 11 opting for a third. In addition a “silicone blend” is not the same as true silicone. Patients were able to resume all activity as normal, including sexual intercourse, immediately after each treatment.